NY, NY—(7/15/2013) – Critical Outcome Technologies’ CEO Dr. Wayne Danter took time to update the investment community on COT’s recent news and progress. During his in-depth interview with The Wall Street Analyst, Dr. Danter discusses the first commercial project from their core technology, COTI-2. He believes it will be in phase 1 by the end of the year and foresees the trends in the sector going towards gene therapies. In addition, he compares the way people will be able to access their technologies to the way consumers access iTunes, via a web portal. Dr. Danter also talks about his background and experience as well as management’s key goal of partnering their lead asset and rolling out the CHEFIRM application. Dr. Danter adds that COT is not a one-trick pony: their technology allows them to pursue multiple projects simultaneously, which he feels sets them apart from other bio-tech companies.
For More Information Please Contact:
Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416‐500‐8061
Email: trevor@heislercommunications.com
Email: wdanter@criticaloutcome.com
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
